Article

Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial

Michael J. Patan 1, David O. Kennedy 1, Cathrine Husberg 2, Svein Olaf Hustvedt 2, Philip C. Calder 3,4, Benita Middleton 5, Julie Khan 1, Joanne Forster 1, and Philippa A. Jackson 1,*

1 Brain, Performance and Nutrition Research Centre, Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK; Michael.j.Patan@northumbria.ac.uk (M.J.P.); david.kennedy@northumbria.ac.uk (D.O.K.); julie.khan@northumbria.ac.uk (J.K.); jo.forster@northumbria.ac.uk (J.F.)
2 BASF AS, NO-0283 Oslo, Norway; Cathrine.Husberg@basf.com (C.H.); Svein.Olaf.Hustvedt@basf.com (S.O.H.)
3 Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK; PC.Calder@soton.ac.uk
4 National Institute of Health Research Southampton Biomedical Research Centre, University Hospital Southampton National Health Service Foundation Trust and University of Southampton, Southampton SO16 6YD, UK
5 Faculty of Health & Medical Sciences, University of Surrey, Guildford GU2 7XH, UK; b.middleton@surrey.ac.uk
* Correspondence: Philippa.jackson@northumbria.ac.uk; Tel.: +44-(0)-191-227-4468

Abstract: Emerging evidence suggests that adequate intake of omega-3 polyunsaturated fatty acids (n-3 PUFAs), which include docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), might be associated with better sleep quality. N-3 PUFAs, which must be acquired from dietary sources, are typically consumed at suboptimal levels in Western diets. Therefore, the current placebo-controlled, double-blind, randomized trial, investigated the effects of an oil rich in either DHA or EPA on sleep quality in healthy adults who habitually consumed low amounts of oily fish. Eighty-four participants aged 25–49 years completed the 26-week intervention trial. Compared to placebo, improvements in actigraphy sleep efficiency ($p = 0.030$) and latency ($p = 0.026$) were observed following the DHA-rich oil. However, these participants also reported feeling less energetic compared to the placebo ($p = 0.041$), and less rested ($p = 0.017$), and there was a trend towards feeling less ready to perform ($p = 0.075$) than those given EPA-rich oil. A trend towards improved sleep efficiency was identified in the EPA-rich group compared to placebo ($p = 0.087$), along with a significant decrease in both total time in bed ($p = 0.032$) and total sleep time ($p = 0.019$) compared to the DHA-rich oil. No significant effects of either treatment were identified for urinary excretion of the major melatonin metabolite 6-sulfatoxymelatonin. This study was the first to demonstrate some positive effects of dietary supplementation with n-3 PUFAs in healthy adult normal sleepers, and provides novel evidence showing the differential effects of n-3 PUFA supplements rich in either DHA or EPA. Further investigation into the mechanisms underpinning these observations including the effects of n-3 PUFAs on sleep architecture are required.

Keywords: docosahexaenoic acid; eicosapentaenoic acid; omega-3; sleep; actigraphy; SMEDS

1. Introduction

The relationship between diet, which includes both specific dietary components and eating behaviors, and sleep quality and duration, is complex and bi-directional in nature [1]. Whilst emerging evidence suggests that obesity and following a high-fat, high-carbohydrate diet might be detrimental to sleep, conversely, improving micronutrient status (e.g., iron, zinc, magnesium, vitamin D, vitamin B12) and consumption of particular whole foods (e.g., milk, kiwi, tart cherries, oily fish) might have beneficial effects [2,3]. Oily fish is rich in
the omega-3 polyunsaturated fatty acids (n-3 PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are not easily produced endogenously in humans and so must be acquired from the diet. EPA and DHA are incorporated into the membranes of cells throughout the body, and DHA is particularly enriched in the brain. As such, adequate intake of these important fatty acids ensures proper functioning across multiple systems. Indeed, low levels of circulating n-3 PUFAs were observed in a wide range of psychopathologies, including attention deficit hyperactivity disorder, major depression, and Alzheimer’s disease [4].

Converging evidence suggests n-3 PUFAs are also important for sleep. Studies of dietary deficiency of n-3 PUFAs in experimental animals revealed a number of mechanisms through which DHA might specifically affect sleep regulation, including impaired functioning of the superchiasmatic nuclei [5], altered melatonin release [6], and disruption to endocannabinoid signaling [7]. With regard to behavioral effects, n-3 PUFA deficiency in rodents results in disorganized sleep patterns [6], an observation that was paralleled in children during a period of total parenteral nutrition devoid of lipids [8]. In humans, higher maternal levels of DHA appear to be linked to more mature infant sleep patterns [9,10]. Further, lower levels of DHA and a lower ratio of DHA to arachidonic acid (an n-6 PUFA) were negatively associated with parent ratings of children’s total sleep disturbance [11]. Likewise, the concentration of n-3 PUFAs in adipose tissue of patients with obesity suffering from sleep apnea was positively associated with sleep efficiency and minutes spent in slow wave sleep and rapid eye movement (REM) sleep [12].

Results from an exploratory pilot trial in children (n = 43, age 7–9 years) indicated that dietary supplementation with DHA might improve objectively measured sleep [11]. However, more data are needed. In addition, to our knowledge no studies evaluated the effects of EPA, which might also be relevant, given the previously observed effects of n-3 PUFAs on serotonin release [13] and the production of prostaglandins [14]; prostaglandin D2, in particular, is a potent somnogen known to mediate the sleep/wake cycle [15]. Therefore, the present study investigated the effects of 26 weeks’ supplementation with oils rich in either DHA or EPA on subjective and objective sleep quality in healthy, adult, low consumers of oily fish.

2. Materials and Methods

2.1. Study Design

This study employed a randomized, placebo-controlled, double-blind, parallel groups design. Participants were randomly assigned to receive one of three treatments for 26 weeks (placebo, DHA-rich oil, EPA-rich oil).

2.2. Participants

Prior to screening, all participants received information about the study and its procedures and signed an informed consent form. Participants were aged between 25–49 years and had to pass a physical/lifestyle screening to demonstrate they were in good health. Participants self-reported consumption of oily fish of less than once per week, measured via a DHA food frequency questionnaire [16]. Having good health was identified as being a non-smoker, free from prescription, herbal, illicit, or recreational drugs (females taking the contraceptive pill were included), free from major illnesses, having a blood pressure lower than 159/99 mmHg and a BMI between 18.5 and 35 kg/m². All participants were recruited via posters, adverts placed on social media websites, or emails sent out to university staff and students, and were either students or staff attending/working at Northumbria University or individuals living in the Newcastle-upon-Tyne surrounding area.

Ninety-five males and females were screened for eligibility, 90 were enrolled into the study and 84 completed all study requirements. Of the six participants that did not complete the study, four were lost to follow-up after completion of the baseline testing visit, one withdrew consent and one was advised to stop adhering to the consumption of supplements due to reports of minor adverse events. Participant disposition throughout
the trial is displayed in Figure 1, demographic data are shown in Table 1 and outcomes from the DHA food frequency questionnaire are shown in Table 2.

Figure 1. Participant disposition through the trial. Figure depicts the disposition of participants throughout the study, culminating in n = 84 of the 90 who were randomized.

2.3. Sample Size

Sample size was calculated based on a medium effect size reported by Montgomery et al. [11] for total minutes asleep measured via actigraphy, following 16 weeks’ supplementation with DHA. Given this effect size, an a priori calculation of the size of sample required in order to detect a significant difference between the groups given 80% power and an alpha level of 0.05, was 30 participants per treatment arm, inclusive of a 10% anticipated dropout rate. Power calculations were made using GPower 3.1.3.

2.4. Randomization

Treatment group was assigned randomly, according to a randomization schedule produced using the website www.randomization.com. To ensure blinding was maintained throughout the study, a third party within the same university created the randomization schedule and coded treatments before the treatments and randomization schedule were delivered to the research team. Capsules were provided in opaque containers. Therefore, both the research team and participants were blind as to which participants received which treatment, until after data analysis was complete.
Table 1. Demographic information and baseline characteristics for the 84 participants who completed all aspects of the study. Means ± SD are given where appropriate. Baseline differences were assessed using separate one-way ANOVAs or chi-square tests; resulting $p$ values from these analyses are presented.

| Variable                  | Treatment        | Mean | SD  | $p$ |
|---------------------------|------------------|------|-----|-----|
| n (Males/Females)         | Placebo 8/20     | -    | -   | 0.886 |
|                           | DHA-rich 7/22    | -    | -   |       |
|                           | EPA-rich 8/19    | -    | -   |       |
| % of EPA in RBC           | Placebo 0.82     | 0.21 |     | 0.169 |
|                           | DHA-rich 0.89    | 0.28 |     |       |
|                           | EPA-rich 1.05    | 0.67 |     |       |
| % of DHA in RBC           | Placebo 0.82     | 0.21 |     | 0.637 |
|                           | DHA-rich 0.89    | 0.28 |     |       |
|                           | EPA-rich 1.05    | 1.50 |     |       |
| n-3 index (EPA + DHA)     | Placebo 5.69     | 1.01 |     | 0.455 |
|                           | DHA-rich 5.63    | 1.06 |     |       |
|                           | EPA-rich 6.10    | 2.00 |     |       |
| Age (years)               | Placebo 36.89    | 7.78 |     | 0.768 |
|                           | DHA-rich 37.41   | 7.28 |     |       |
|                           | EPA-rich 35.89   | 8.73 |     |       |
| Systolic BP (mmHg)        | Placebo 122.80   | 11.19|     | 0.699 |
|                           | DHA-rich 120.21  | 13.04|     |       |
|                           | EPA-rich 120.50  | 13.43|     |       |
| Diastolic BP (mmHg)       | Placebo 81.00    | 8.12 |     | 0.805 |
|                           | DHA-rich 79.45   | 9.67 |     |       |
|                           | EPA-rich 79.81   | 9.82 |     |       |
| Heart Rate (BPM)          | Placebo 71.70    | 12.36|     | 0.439 |
|                           | DHA-rich 69.50   | 11.38|     |       |
|                           | EPA-rich 73.43   | 10.42|     |       |
| Weight (kg)               | Placebo 73.92    | 17.45|     | 0.656 |
|                           | DHA-rich 70.37   | 12.20|     |       |
|                           | EPA-rich 72.11   | 14.40|     |       |
| Height (cm)               | Placebo 168.83   | 9.85 |     | 0.614 |
|                           | DHA-rich 166.59  | 6.01 |     |       |
|                           | EPA-rich 167.65  | 8.48 |     |       |
| BMI (kg/m$^2$)            | Placebo 25.76    | 4.59 |     | 0.936 |
|                           | DHA-rich 25.36   | 4.24 |     |       |
|                           | EPA-rich 25.62   | 4.48 |     |       |
| Years in Education        | Placebo 16.28    | 1.10 |     | 0.239 |
|                           | DHA-rich 15.56   | 1.74 |     |       |
|                           | EPA-rich 15.96   | 1.61 |     |       |
| Fruit & Vegetable (portions per day) | Placebo 4.13 | 1.78 |     | 0.359 |
|                           | DHA-rich 4.48    | 2.21 |     |       |
|                           | EPA-rich 4.11    | 1.93 |     |       |
| Alcohol (units per day)   | Placebo 1.00     | 0.71 |     | 0.157 |
|                           | DHA-rich 1.27    | 1.05 |     |       |
|                           | EPA-rich 1.23    | 0.85 |     |       |
Table 2. Outcomes from the DHA food frequency questionnaire for the 84 participants who completed all aspects of the study. Group differences were assessed using separate one-way ANOVAs; resulting p values from these analyses are presented.

| N-3 PUFA Food Source | Treatment | Mean  | SD    | p       |
|----------------------|-----------|-------|-------|---------|
| Oily fish, servings per month a | Placebo   | 1.43  | 1.45  | 0.522   |
|                      | DHA-rich  | 1.79  | 1.55  |         |
|                      | EPA-rich  | 1.85  | 1.48  |         |
| Fish, servings per month b | Placebo   | 2.07  | 1.54  | 0.834   |
|                      | DHA-rich  | 2.05  | 1.76  |         |
|                      | EPA-rich  | 2.33  | 2.41  |         |
| Fish/shellfish, servings per month c | Placebo   | 1.36  | 1.70  | 0.402   |
|                      | DHA-rich  | 1.90  | 1.81  |         |
|                      | EPA-rich  | 1.39  | 1.50  |         |
| Liver, servings per month d  | Placebo   | 2.04  | 4.78  | 0.381   |
|                       | DHA-rich  | 0.78  | 1.84  |         |
|                       | EPA-rich  | 1.93  | 4.12  |         |
| Egg yolks, servings per week | Placebo   | 4.11  | 3.62  | 0.890   |
|                        | DHA-rich  | 4.52  | 4.12  |         |
|                        | EPA-rich  | 4.69  | 5.77  |         |
| Poultry, servings per week | Placebo   | 2.93  | 2.36  | 0.534   |
|                        | DHA-rich  | 3.53  | 2.59  |         |
|                        | EPA-rich  | 2.87  | 2.44  |         |

a includes bluefish, blue fin tuna, cisco (smoked), herring, mackerel, pollock, sardines, salmon, whitefish; b includes bass, calamari, catfish, drumfish, flounder, grouper, halibut, mussels, perch, redfish, rockfish, shark, snapper, sole, squid, swordfish, trout, tuna (canned 6 oz), whiting; c includes carp, clams, cod, crab, crayfish, fish patties/squares, fish sticks, haddock, lobster, mullet, oysters, pike, pompano, scallops, shrimp (14 medium), surgeon; and d includes chicken liver, turkey liver, or beef liver.

2.5. Treatment

All treatment capsules were supplied by BASF AS. Treatment was provided as three 1 g capsules. The DHA-rich capsules provided 900 mg DHA/d and 270 mg EPA/d (Accelon™ DHA EE EU capsules), the EPA-rich capsules provided 360 mg DHA/d and 900 mg EPA/d (Accelon™ EPA EE EU capsules) and the placebo capsules contained 1 g refined olive oil. Each capsule of Accelon High DHA contained 600 mg oil with at least 420 mg omega-3 fatty acid EEs, including EPA, DHA, C18:3 n-3, C18:4 n-3, C20:4 n-3, C21:5 n-3, and C22:5 n-3. The amount of DHA was at least 300 mg and EPA at least 90 mg per capsule. Similarly, each capsule of Accelon High EPA contained 600 mg oil with at least 450 mg omega-3 fatty acid EEs, including the same fatty acids as above. The amount of DHA was at least 120 mg and EPA was at least 300 mg per capsule. The additional capsule fill, 400 mg/capsule for both formulations, was food additives (permitted for use in food supplements). The active treatments using the Accelon™ technology also contained a proprietary mixture of surfactants and co-solvents. When exposed to the contents of the stomach, these ingredients are designed to spontaneously emulsify the oils, forming microdroplets. Known as a self-microemulsifying delivery system (SMEDS), this approach improves the absorption of the n-3 PUFAs contained within the treatments [17]. Participants were instructed to take their capsules with a glass of water at their usual bedtime. Placebo and treatment capsules were identical in size and shape, and similar in appearance.

2.6. Procedure

All study visits took place at Northumbria University’s Brain, Performance, and Nutrition Research Centre (BPNRC). Potential participants attended the centre for an initial screening visit. The principal investigator or designee discussed with each participant the nature of the trial, its requirements and restrictions, in line with the participant information sheet previously given to the participant. Formal written consent was provided.
Before the baseline and week 26 assessments, participants were required to visit the center to collect an actiwatch, sleep diary, and urine sampling pack. Participants were required to wear the actiwatch and complete the sleep diary for the 7 nights, prior to the baseline and week 26 assessments, and to provide urine samples the night before and the morning of the baseline and week 26 assessments. Participants were asked to avoid alcohol and refrain from intake of ‘over the counter’ medications for 24 h and of caffeine for 18 h before both the baseline and week 26 assessments. Participants were contacted to remind them of the requirements prior to each assessment. On the morning of the baseline testing visit, participants were requested to eat their usual breakfast at least 1 h prior to arrival at the laboratory (but to avoid any caffeinated products) or to not have breakfast if they usually skipped breakfast. At the end of the baseline assessments, participants were provided with the first batch of capsules (3 bottles of 100 capsules each) and given a diary in which to record their daily consumption of capsules, along with any adverse events and concomitant medications (see Supplementary Figure S1 for schematic depiction of the study overview).

Participants also reported to the BPNRC during week 13 to collect the second batch of capsules (3 bottles of 100 capsules each) and to complete the Leeds Sleep Evaluation Questionnaire (LSEQ) and subjective awakening scales. Participants also brought with them their diary, which was replaced with a new diary to complete between week 13–26, and any remaining unused treatment capsules, so that a treatment compliance percentage could be calculated.

The week 26 testing assessment was identical to the baseline assessment in all aspects, apart from collecting the treatment and sleep diaries, all remaining treatments, completion of a treatment guess questionnaire, and finally a full debrief once all assessments were completed. During both baseline and week 26 visits, participants were also required to provide a 6 mL venous blood sample to determine red blood cell fatty acid profile.

2.7. Outcomes

2.7.1. Subjective Measures

The LSEQ is a 10-item visual analog scale (VAS) specifically designed to measure changes in subjective sleep, following a pharmacological intervention [18]. The questionnaire measures aspects of sleep including Getting to Sleep, Quality of Sleep, Awakening from Sleep, and Behavior Following Sleep. The 10 items that made up the four sleep components were each presented on a 100 mm line with one end representing a negative and the other representing a positive response to the question. Higher scores on these scales represented more positive feelings of the respective items.

The VAS measured items related to participant’s subjective awakening state. Participants rated their current subjective state by making a mark on a 100 mm line with the end-points labelled “not at all” (left hand end) and “very much so” (right hand end). These scales included the following questions “how rested do you feel?”, “how energetic do you feel?” “how relaxed do you feel?”, “how ready do you feel to perform”, and “have you had a good night’s sleep?”. Higher scores on these scales represent stronger feelings of the respective items.

2.7.2. Biological Measures

Urine sampling commenced on the evening prior to the baseline and week 26 testing visits and comprised three separate samples—void at bedtime and the first and second voids of the following day (morning of the testing visit). If a participant needed to urinate during the night, then these voids were also collected in the same manner, as described below.

Urine was collected in a sterilized measuring cylinder. Void volume, time and date were recorded, before a 10 mL aliquot of urine was retained and refrigerated in a screw cap container, pre-labelled with the participant’s study details. The samples were taken to the laboratory at the baseline and week 26 testing visits, for further labelling and immediate
storage at −80 °C for later analysis of the major melatonin metabolite 6-sulfatoxymelatonin (aMT6s), using radioimmunoassay [19].

Total excretion of aMT6s (ng) summed from all voids and the bedtime aMT6s (ng) values were calculated. Bedtime excretion of aMT6s specifically was also chosen to be analyzed independently from the total aMT6s, as a measure of melatonin production before sleeping, in an attempt to assess the effects of treatment on bedtime melatonin levels. This is because reduced evening melatonin production is associated with sleep disturbances [20], and urinary levels of aMT6s are seen to parallel those of melatonin in the blood, saliva, and urine [21].

2.7.3. Objective Measures

Participants were instructed to complete sleep diaries to record time in and out of bed, and to wear actigraphy WGT3X-BT watches (ActiGraph LLC, Pensacola, FL, USA) on the non-dominant wrist for seven consecutive days and nights, both prior to commencing and before completing the 26-week supplementation period. The devices were small and lightweight and could detect body accelerations in the vertical, horizontal (right to left), and frontal (front and back) planes, at varying sample rates. The data from the watches were collected in 1-min epochs. Utilizing Actilife software (version 6.1, ActiGraph, Pensacola, FL, USA) and the Cole-Kripke algorithm [22], the following parameters could then be calculated:

- Sleep latency (The difference in minutes between In-Bedtime and sleep onset).
- Sleep efficiency (Number of sleep minutes divided by the total number of minutes the participant was in bed, i.e., the difference between the In-Bed and Out-Bedtime).
- Total sleep time (The total number of minutes scored as “asleep”).
- Total minutes in bed (The total number of minutes in bed both awake and asleep).
- Wake after sleep onset (The total number of minutes awake after sleep onset occurred).
- Number of awakenings (Total number of awakenings from the time spent in bed).
- Average awakening length (The average length, in minutes, of all awakening episodes).
- Sleep Fragmentation Index (The sum of the Movement Index—Total of scored awake minutes divided by Total time in bed in hours × 100 and the Fragmentation Index—Total of 1-min scored sleep bouts divided by the total number of sleep bouts of any length × 100)

2.8. Red Blood Cell Fatty Acid Measurements

Blood samples were collected via venepuncture into ethylenediaminetetraacetic acid vacutainers (6 mL) by trained phlebotomists. The samples were stored in an ice box, or at 5 °C, until they could be processed, which was within 8 h of collection. Blood was centrifuged at 2000 rpm (913 × g) for 10 min at room temperature. The top layer of plasma was then removed and discarded. One ml of the red blood cell (RBC) pellet was collected, transferred to a 15 mL centrifuge tube and the volume was increased to 15 mL with phosphate-buffered saline (PBS). The mixture was inverted and centrifuged at 1200 rpm (350 × g) for 10 min, at room temperature, with a low brake. The PBS was then removed and the washing process repeated for a second time. After the second wash, the RBC pellet was transferred into 1.5 mL microtubes and immediately frozen at −80 °C, prior to analysis.

RBC fatty acid composition was analyzed by gas chromatography [23]. The RBC pellet was washed twice with 5 mL of 0.9% sodium chloride (NaCl) and then total lipid was extracted using chloroform–methanol (2:1) containing 50 mg/L butylated hydroxytoluene as an antioxidant. The lipid phase was dried down under nitrogen, redissolved in a small volume of toluene, and then heated for 2 h at 50 °C with dry methanol containing 2% sulfuric acid. This procedure cleaved fatty acids from more complex lipids (e.g., membrane phospholipids) and simultaneously methylated them to produce fatty acid methyl esters (FAMEs). At the end of the reaction time, the sample was neutralized and FAMEs were extracted into hexane. FAMEs were concentrated and then separated on an Agilent 6890 gas
chromatograph fitted with a 30-m long SGE BPX-70 fused silica capillary column. The split ratio was 25:1. The injector port temperature was 300 °C and helium was used as the carrier gas. The oven was held at 115 °C for 2 min, then increased at a rate of 10 °C per minute up to 200 °C, where it was held for 18.5 min. Oven temperature was then increased at a rate of 60 °C per minute to 245 °C, where it was held for 4 min. The flame ionization detector was held at 300 °C. FAMEs were identified by comparison with run times of authentic standards. Peak areas were calculated using the ChemStation software and each FAME was expressed as a weight % of the total. The n-3 index was calculated as % EPA + % DHA.

2.9. Compliance and Treatment Guess

As each participant was provided with 600 treatment capsules throughout the supplementation period, treatment compliance (%) could be calculated in order to measure adherence to the study protocol, with regards to appropriate consumption of the study treatments. Treatment compliance was calculated by comparing the number of capsules that were returned by each participant at the end of the study with the number of capsules that were to be returned.

Additionally, at the end of the study, all participants were provided with a treatment guess questionnaire and asked to choose between whether they had received an active or placebo treatment throughout the supplementation period, to verify the blinding procedure. Responses from the treatment guess questionnaire were analyzed via the chi-square test, comparing the number of correct and incorrect responses given by each treatment group.

2.10. Statistical Methods

Statistical analyses were performed with the IBM SPSS statistics software (version 25; IBM Corp, Armonk, NY, USA). Full data handling and cleaning procedures are described in the Supplementary Materials Section 2. Descriptive and comparison statistics (independent t-test, two-tailed, or chi-square test) of all baseline characteristics were based on all participants who were randomized and consumed at least one dose of treatment. All other analyses conducted were from the intention-to-treat (ITT) population. The general statistical approach selected to analyze the repeated measures data by treatment group was via linear mixed models (LMM) with treatment (DHA-rich, EPA-rich, placebo) and night (1–7) as factors in the objective sleep models and treatment (DHA-rich, EPA-rich, placebo), and visit (week 13 and week 26) in the subjective models. For each model that was run, the covariance matrix structure was chosen on the basis of structure that produced the lowest Schwarz’s Bayesian Criterion (BIC), an indication of the best fitting model for the data [24]. Changes within outcome variables during the treatment period were assessed via LMMs that adjusted for the respective baseline scores. Significant main or interaction effects of treatment (p < 0.050) were further investigated with Sidak-corrected comparisons to account for multiple group comparisons.

2.11. Ethics

This study was pre-registered via www.clinicaltrials.gov (NCT03559361) and conducted at the University of Northumbria, according to the guidelines of the Declaration of Helsinki (2013). Ethical approval for the trial was obtained from the University of Northumbria, Department of Psychology Ethics Committee (SUB023), and written informed consent was obtained from all participants. All paper study data were stored in a locked filing cabinet and electronic data on a secure network drive with access granted only to those working within the research center. The trial described in this manuscript was a sub-study of a larger study investigating the effects of the EPA- and DHA-rich oils on cognitive function (NCT02763514).
3. Results

The flow of participants through the study is summarized in Figure 1. The final analysis was conducted in 84 participants (n = 28 in the placebo group; n = 29 in the DHA-rich oil group; n = 27 in the EPA-rich oil group) for whom baseline and end of study data were available. Baseline characteristics of subjects are summarized in Table 1. No significant differences between the treatment groups were identified for any baseline demographics.

3.1. Compliance

For participants who completed the study, compliance was observed to be very good in all three groups (95.21% Placebo, 96.42% DHA-rich, 95.64% EPA-rich), with one-way ANOVA identifying no significant differences for compliance percentage by treatment group \(F(2, 81) = 0.274, p = 0.761\). A chi-square test was also conducted on the responses to the treatment guess questionnaire that was completed at the end of the final visit and revealed no significant differences in participants’ ability to correctly identify whether they were administered an active or placebo treatment between the three groups \(\chi^2(2) = 3.84, p = 0.147\). Analysis of RBC fatty acid profiles further supports the compliance data, with increases in EPA, DHA and \(n\)-3 index in both EPA and DHA groups (Table 3). This increase was more marked in the DHA than the EPA group (Table 3).

Table 3. Red blood cell EPA, DHA, and \(n\)-3 index for placebo, DHA-rich, and EPA-rich treatment groups. Data are mean ± SD at baseline, week 26, and change (from baseline).

| Variable                  | Treatment   | Baseline \((n = 80)\) | Week 26 \((n = 70)\) | Change * \((n = 69)\) |
|---------------------------|-------------|------------------------|-----------------------|------------------------|
| % of EPA in RBC           | Placebo     | 0.82 ± 0.21            | 0.80 ± 0.27           | −0.03 ± 0.19           |
|                           | DHA-rich    | 0.88 ± 0.28            | 2.16 ± 0.57           | 1.24 ± 0.57            |
|                           | EPA-rich    | 1.03 ± 0.43            | 2.73 ± 1.02           | 1.68 ± 1.03            |
| % of DHA in RBC           | Placebo     | 4.82 ± 0.96            | 4.77 ± 0.82           | 0.03 ± 0.78            |
|                           | DHA-rich    | 4.71 ± 0.91            | 7.69 ± 1.31           | 2.94 ± 1.42            |
|                           | EPA-rich    | 5.04 ± 1.48            | 6.12 ± 0.95           | 1.08 ± 1.43            |
| \(n\)-3 index (EPA + DHA) | Placebo     | 5.63 ± 1.03            | 5.57 ± 0.95           | −0.00 ± 0.80           |
|                           | DHA-rich    | 5.59 ± 1.06            | 9.85 ± 1.64           | 4.18 ± 1.69            |
|                           | EPA-rich    | 6.07 ± 1.94            | 8.85 ± 1.60           | 2.75 ± 2.19            |

* Change values are only calculated for those participants who had data at both baseline and week 26.

3.2. Mixed Models Analysis

Due to the number of possible interactions between the factors, only those that revealed significant main or interaction effects, including treatment, are reported.

3.2.1. Objective Measures

See Table 4 for a summary of all objective sleep results. A significant main effect of treatment for sleep efficiency was identified \(F(2, 79.79) = 3.68, p = 0.030\) with post-hoc comparisons identifying the DHA-rich group (92.02%; \(p = 0.037\)) as having significantly higher sleep efficiency, with a trend towards significantly higher sleep efficiency in the EPA-rich group (91.85%; \(p = 0.087\)) as compared to placebo (90.30%) (Figure 2A).

Analysis identified a significant main effect of treatment for sleep latency \(F(2, 322) = 3.68, p = 0.026\) with post-hoc comparisons identifying the DHA-rich (3.76; \(p = 0.021\)) but not the EPA-rich (3.98; \(p = 0.276\)) group as showing significantly shorter sleep latency, as compared to placebo (4.31) (Figure 2B).

Analysis also identified a significant interaction between treatment and night for sleep latency \(F(12, 322) = 2.28, p = 0.009\), with post-hoc comparisons identifying the DHA-rich group (3.31) as having a significantly shorter latency period compared to both the placebo (6.43; \(p = 0.003\)) and the EPA-rich (5.80; \(p = 0.023\)) groups on night 1, and both the DHA-rich (3.36, \(p = 0.017\)) and EPA-rich (3.34, \(p = 0.021\)) groups as having a significantly shorter latency period compared to placebo (4.53) on night 6.
Table 4. Objective sleep outcomes for the placebo, DHA-rich, and EPA-rich treatment groups. Post-dose estimated marginal means and standard error (SE) are presented with F and p values of the main effects from the linear mixed models.

| Variable                              | Treatment | Post-Dose | Main Effects |
|---------------------------------------|-----------|-----------|--------------|
|                                       |           | n | Mean | SE | F   | p   |
| latency (minutes)                     | Placebo   | 74 | 4.31 ^a | 0.21 | Treatment | 3.68 | 0.026 |
|                                       | DHA-rich  | 74 | 3.76 ^a | 0.26 | Treatment | 3.68 | 0.026 |
|                                       | EPA-rich  | 74 | 3.98  | 0.27 | Treatment | 2.28 | 0.009 |
|                                       |           |    |       |     | Treatment × Night | 1.47 | 0.138 |
| efficiency (%)                        | Placebo   | 72 | 90.30 ^b,T | 0.50 | Treatment | 3.68 | 0.030 |
|                                       | DHA-rich  | 72 | 92.02 ^a | 0.49 | Treatment | 3.68 | 0.030 |
|                                       | EPA-rich  | 72 | 91.85 ^T | 0.57 | Treatment | 1.47 | 0.138 |
|                                       |           |    |       |     | Treatment × Night | 0.851 | 0.598 |
| total minutes in bed (minutes)        | Placebo   | 74 | 484.51 | 8.13 | Treatment | 3.29 | 0.039 |
|                                       | DHA-rich  | 74 | 494.85 ^b | 6.63 | Treatment | 3.29 | 0.039 |
|                                       | EPA-rich  | 74 | 467.10 ^b | 8.55 | Treatment | 0.851 | 0.598 |
|                                       |           |    |       |     | Treatment × Night | 1.20 | 0.281 |
| total sleep time (minutes)            | Placebo   | 73 | 437.91 | 7.56 | Treatment | 4.06 | 0.018 |
|                                       | DHA-rich  | 73 | 455.17 ^b | 6.18 | Treatment | 4.06 | 0.018 |
|                                       | EPA-rich  | 73 | 427.28 ^b | 8.08 | Treatment | 1.20 | 0.281 |
|                                       |           |    |       |     | Treatment × Night | 0.813 | 0.446 |
| wake after sleep onset (minutes)       | Placebo   | 72 | 42.02 | 2.42 | Treatment | 2.55 | 0.084 |
|                                       | DHA-rich  | 72 | 35.84 | 2.14 | Treatment | 2.55 | 0.084 |
|                                       | EPA-rich  | 72 | 34.77 | 2.74 | Treatment | 1.29 | 0.225 |
|                                       |           |    |       |     | Treatment × Night | 1.19 | 0.289 |
| number of awakenings                  | Placebo   | 74 | 17.50 | 0.99 | Treatment | 0.813 | 0.446 |
|                                       | DHA-rich  | 74 | 15.87 | 0.88 | Treatment | 0.813 | 0.446 |
|                                       | EPA-rich  | 74 | 16.20 | 1.08 | Treatment | 1.19 | 0.289 |
|                                       |           |    |       |     | Treatment × Night | 1.90 | 0.036 |
| average awakening length (minutes)    | Placebo   | 74 | 2.44  | 0.11 | Treatment | 0.576 | 0.564 |
|                                       | DHA-rich  | 74 | 2.29  | 0.09 | Treatment | 0.576 | 0.564 |
|                                       | EPA-rich  | 74 | 2.38  | 0.12 | Treatment | 1.50 | 0.126 |
|                                       |           |    |       |     | Treatment × Night | 1.50 | 0.126 |
| sleep fragmentation index             | Placebo   | 74 | 22.89 | 1.28 | Treatment | 0.802 | 0.451 |
|                                       | DHA-rich  | 74 | 20.80 | 1.11 | Treatment | 0.802 | 0.451 |
|                                       | EPA-rich  | 74 | 22.22 | 1.38 | Treatment | 1.90 | 0.036 |
|                                       |           |    |       |     | Treatment × Night | 1.90 | 0.036 |

^a = significant difference between active and placebo groups, p < 0.050; ^b = significant difference between the active treatment groups, p < 0.050; ^T = trend towards a significant difference between active and placebo groups, p < 0.100.

Analysis identified a significant main effect of treatment for total minutes in bed \( [F (2, 328) = 3.29, p = 0.039] \), with post-hoc comparisons identifying no significant differences between the active and placebo groups, but the DHA-rich group (484.51 min) spent significantly more time in bed than the EPA-rich group (467.10; \( p = 0.032 \)) (Figure 2C).

A significant main effect of treatment was also identified for total sleep time \( [F (2, 323) = 4.06, p = 0.018] \) with post-hoc comparisons identifying no significant differences between the active and placebo groups but the DHA-rich group (455.17 min) spent significantly more time asleep than the EPA-rich group (427.28; \( p = 0.019 \)) (Figure 2D).

Analysis also identified a significant interaction between treatment and night for the sleep fragmentation index \( [F (12, 227.64) = 1.90, p = 0.025] \), with post-hoc comparisons identifying the DHA-rich group (15.88; \( p = 0.003 \)) as having significantly less sleep fragmentation compared to placebo (26.85) on night 2 only.
3.2.2. Subjective Measures

See Table 5 for a full summary of subjective sleep results. A significant effect of treatment for feeling energetic was also identified \([F (2, 79.35) = 3.545, p = 0.034]\), with post-hoc comparisons identifying the DHA-rich (53.79; \(p = 0.041\)) but not the EPA-rich (64.94; \(p = 0.970\)) group as feeling significantly less energetic, as compared to the placebo (62.47) (Figure 3).

A significant effect of treatment for feeling rested was identified \([F (2, 76.42) = 4.71, p = 0.017]\), with post-hoc comparisons identifying no significant difference between the active and placebo groups, but the DHA-rich group (53.55) were significantly less rested than the EPA-rich group (64.94; \(p = 0.017\)) (Figure 3).

A significant effect of treatment for feeling ready to perform was identified \([F (2, 84.12) = 3.211, p = 0.045]\), with post-hoc comparisons identifying no significant difference between
the active and placebo groups but the DHA-rich group (59.12) showed a trend towards being significantly less ready to perform than the EPA-rich group (66.65; $p = 0.075$) (Figure 3).

Table 5. Subjective sleep outcomes for the placebo, DHA-rich, and EPA-rich treatment groups. Estimated marginal means and standard error (SE) for week 13 and week 26 are presented with F and $p$ values of the main effects from the linear mixed models.

| Variable | Treatment | Week 13 | Week 26 | Main Effects |
|----------|-----------|---------|---------|--------------|
|          | n | Mean | SE | Mean | SE | Treatment | F | p |
| Getting to Sleep (0–300) | | | | | | | | |
| Placebo  | 86 | 182.49 | 6.69 | 170.63 | 6.69 | Treatment | 0.243 | 0.785 |
| DHA-rich | 177.13 | 7.28 | 177.05 | 6.56 | | Treatment | 0.557 | 0.575 |
| EPA-rich | 176.04 | 7.09 | 167.88 | 6.98 | | | |
| Quality of Sleep (0–200) | | | | | | | | |
| Placebo  | 86 | 118.12 | 6.65 | 112.38 | 6.74 | Treatment | 0.438 | 0.647 |
| DHA-rich | 118.47 | 7.19 | 118.64 | 6.53 | | Treatment | 0.392 | 0.677 |
| EPA-rich | 112.80 | 6.37 | 113.05 | 6.27 | | | |
| Awake Following Sleep (0–200) | | | | | | | | |
| Placebo  | 86 | 107.23 | 6.01 | 113.52 | 6.12 | Treatment | 0.518 | 0.598 |
| DHA-rich | 118.80 | 6.62 | 115.34 | 5.91 | | Treatment | 0.379 | 0.686 |
| EPA-rich | 118.64 | 6.53 | 113.39 | 6.27 | | | |
| Behaviour Following Wakening (0–300) | | | | | | | | |
| Placebo  | 86 | 66.21 | 3.67 | 59.80 | 3.74 | Treatment | 4.71 | 0.012 |
| DHA-rich | 56.44 | 4.06 | 50.65 | 3.60 | | Treatment | 0.034 | 0.966 |
| EPA-rich | 68.79 | 3.91 | 61.09 | 3.82 | | | |
| Rested (%) | | | | | | | | |
| Placebo  | 86 | 65.69 | 3.21 | 60.20 | 3.26 | Treatment | 3.55 | 0.034 |
| DHA-rich | 56.35 | 3.56 | 51.23 | 3.16 | | Treatment | 1.05 | 0.354 |
| EPA-rich | 60.42 | 3.42 | 62.51 | 3.37 | | | |
| Energetic (%) | | | | | | | | |
| Placebo  | 86 | 64.88 | 3.21 | 65.82 | 3.26 | Treatment | 1.37 | 0.260 |
| DHA-rich | 61.12 | 3.49 | 58.81 | 3.14 | | Treatment | 0.191 | 0.827 |
| EPA-rich | 65.60 | 3.40 | 65.47 | 3.35 | | | |
| Irritable (%) | | | | | | | | |
| Placebo  | 86 | 26.74 | 3.70 | 27.70 | 3.77 | Treatment | 1.46 | 0.238 |
| DHA-rich | 31.95 | 4.09 | 35.10 | 3.64 | | Treatment | 0.196 | 0.822 |
| EPA-rich | 28.70 | 3.92 | 27.25 | 3.85 | | | |
| Ready to Perform (%) | | | | | | | | |
| Placebo  | 86 | 65.70 | 3.56 | 66.23 | 2.86 | Treatment | 3.21 | 0.045 |
| DHA-rich | 61.56 | 3.08 | 56.68 | 2.76 | | Treatment | 0.668 | 0.515 |
| EPA-rich | 66.88 | 2.98 | 66.43 | 2.92 | | | |
| Good Night’s Sleep (%) | | | | | | | | |
| Placebo  | 86 | 65.88 | 4.30 | 59.53 | 4.38 | Treatment | 1.61 | 0.205 |
| DHA-rich | 63.06 | 4.72 | 50.85 | 4.23 | | Treatment | 0.392 | 0.677 |
| EPA-rich | 68.37 | 4.54 | 62.69 | 4.45 | | | |

$^a$ = significant difference between active and placebo groups, $p < 0.050$; $^b$ = significant difference between the active treatment groups, $p < 0.050$.

A significant treatment by visit interaction for behavior, following waking, was observed [$F (2, 77.01) = 5.03, p = 0.009$]. However, post-hoc comparisons identified no significant differences between any of groups at either week 13 or 26. No other effects of treatment were observed for any other subjective measures.
3.2.3. Biological Measures

No significant main effects of treatment were observed for urinary aMT6s (Table 6).

Table 6. Urinary aMT6s for placebo, DHA-rich, and EPA-rich treatment groups. Post-treatment estimated marginal means and standard error (SE) are presented with the F and p values of the main effects from the linear mixed models.

| Variable               | Treatment    | Post-Treatment | Main Effects |
|------------------------|--------------|----------------|--------------|
|                        | n            | Mean           | SE           | F     | p     |
| Total aMT6s (ng)       | Placebo      | 15,289.27      | 1,267.50     |       |       |
|                        | DHA-rich     | 15,335.89      | 1,267.88     | 0.558 | 0.575 |
|                        | EPA-rich     | 13,585.56      | 1,346.06     |       |       |
| Bedtime aMT6s (ng)     | Placebo      | 563.98         | 120.67       |       |       |
|                        | DHA-rich     | 468.62         | 123.42       | 2.12  | 0.130 |
|                        | EPA-rich     | 805.34         | 117.08       |       |       |

4. Discussion

The results from the current study show that supplementation with DHA-rich oil in healthy adults who do not habitually consume oily fish, resulted in a significant increase in sleep efficiency and a significant decrease in sleep latency compared to placebo. Interestingly, despite these improvements in the objective actigraphy sleep measures in the DHA-rich group, it was also found that this group reported feeling less rested compared to placebo, and less energetic and ready to perform than those given EPA-rich oil. A significant decrease in the sleep fragmentation index was also observed in the DHA-rich group, as compared to the placebo. However, the latter effect was found to only be evident during the second night of the seven nights recorded, and must be interpreted with caution. With regards to the EPA-rich oil, a trend towards a significant increase in sleep efficiency was identified in this group, as compared to the placebo. The EPA-rich oil also resulted in a significant decrease in both total time in bed and total sleep time, as compared to the DHA-rich group, although no significant differences were identified between either treatment group and placebo for these measures. Finally, no significant effects of treatment were identified for urinary aMT6s excretion.

The beneficial effects of DHA in increasing sleep efficiency and reducing sleep latency were consistent with previous animal models [25] and exploratory data from an intervention study in children [11], providing further evidence to support the beneficial role of DHA.
in sleep. Indeed, enzymatic transformation of serotonin to melatonin by aralkylamine N-acetyltransferase [26] was supported by DHA, via its positive effects on membrane fluidity [27] and serotonin levels in the prefrontal cortex [28], which might help modulate the transition between sleep and wakefulness [29]. Given the above, the null findings of treatment on urinary aMT6s might suggest that DHA affects sleep via mechanisms other than the melatonin synthesis pathway. However, it might also be the case that the period of urinary collection over a single night was simply not sensitive enough to identify an effect on aMT6s. Therefore, in order to better evaluate the relationship between n-3 PUFAs, melatonin and sleep, future research should consider either the use of 24/48 h urinary collection periods or the analysis of melatonin in blood, which allows for greater resolution and sensitivity [30].

The negative subjective ratings identified in the DHA-rich oil group were inconsistent with the actigraphy data. One potential explanation for this might be informed by investigations of patients suffering from insomnia. For instance, Feige et al. [31] explain how a major enigma of insomnia research constitutes the frequently noted discrepancy between the subjective experience of sleep (measured by sleep questionnaires) and the polysomnographic (PSG) findings. PSG studies often demonstrate that patients suffering from insomnia tend to underestimate their nocturnal sleep time [32,33], leading to terms such as ‘sleep state misperception’ for patients with a relatively normal sleep continuity and architecture, despite subjective complaints of disturbed sleep [34]. Due to the issues with objectively defining sleep parameters (e.g., sleep efficiency/latency [35]), focusing on the architecture of sleep might offer additional explanations for these conflicting data. For example, Feige et al. [32] showed that differences between subjectively and objectively measured wake times were correlated with the amount of REM sleep in insomnia patients, i.e., patients with higher amounts of REM sleep tended to report more minutes of subjective wakefulness. Further investigation using PSG would therefore provide valuable insights into the effects of n-3 PUFAs on the sleep architecture, in relation to the amounts of REM and non-REM sleep, which could then be evaluated alongside subjective effects.

Regarding the observed effects of EPA-rich oil on sleep, the differential pattern of results compared to placebo and the direct differences between the effects of each treatment do suggest specific roles of DHA and EPA in sleep. The shortened sleep times identified within the current study, following the EPA-rich oil as compared to the DHA-rich oil, might potentially be explained by the role of EPA inhibiting the formation of E2-series prostaglandins, which in turn inhibit the release of serotonin [36]. As serotonin promotes wakefulness and inhibits REM sleep [37], it might be that increased levels of circulating EPA indirectly upregulate the promotion of wakefulness, resulting in decreased sleep time. It should be noted that although participants in the EPA-rich oil group reported the shortest sleep times, this did not appear to lead to any reduction in the quality of sleep. In fact, a trend towards a significant increase in sleep efficiency, compared to placebo, was observed along with no increases in the time spent awake, number of awakenings, or decreased ratings of subjective sleep quality. This might potentially suggest that EPA is beneficial for regulating a healthy sleep cycle and could help protect against suboptimal sleep (i.e., too little or too much sleep), which is known to be detrimental for health [38,39].

The current study was the first to investigate the separate effects of DHA and EPA on sleep, in a sample of healthy, young adults, with a rigorous study protocol that collected both objective and subjective measurements of sleep. Additionally, the measurement of aMT6s offered the potential to gain insight into possible mechanisms underpinning the relationship between n-3 PUFAs and sleep. The study had good compliance, as confirmed by measuring the RBC EPA, DHA, and the n-3 index. However, the study is not without its limitations and several challenges were faced with regards to the collection of actigraphy data, as well as with the subjective recording of sleep/wake times. Issues with incomplete and even unusable actigraph data—as a result of improper use of the equipment—resulted in a reduced sample size in the actigraphy datasets, although this reduction is in line with missing data observed in previous actigraphy studies [11,40]. Furthermore, future
research might wish to take body composition into account when recruiting participants. As overweight and obese individuals are seen to have increased inflammatory profiles [41,42] and are more likely to experience sleep disorders [43], this might be a factor that future trials could control for more strictly or take into consideration during data analysis. As the current study included participants with a BMI ≤ 35 kg/m², it could be that a more conservative range of BMI should be used in future.

Overall, this study provides additional support for the beneficial role of n-3 PUFAs, particularly DHA, for sleep. These include an overall increase in sleep efficiency and a reduction in sleep latency, although these positive measures of increased sleep quality measured using actigraphy were not consistent with subjective ratings, following DHA-rich oil. Further investigations into the relationship between n-3 PUFAs and the serotonin/melatonin synthesis pathway and effects on sleep architecture are required. Nonetheless, as beneficial effects of sleep were identified following supplementation with n-3 PUFAs in healthy, young adults, these data help to provide additional evidence towards the role of n-3 PUFAs in facilitating healthy regulation of sleep.

Supplementary Materials: The following are available online at https://www.mdpi.com/2072-6643/13/1/248/s1. Figure S1: Schematic showing the study progression from enrolment to completion across the 26 weeks. Actigraphy recordings were taken for the seven days and nights prior to the baseline; week 26 testing visits and urinary aMT6s samples were collected the night prior to and morning of the baseline and week 26 testing visits. LSEQ—Leeds Sleep Evaluation Questionnaire.

Author Contributions: Study design and concept, P.A.J., M.J.P., D.O.K., C.H., and S.O.H. Data collection, M.J.P., J.K., and J.F. Data analysis, M.J.P., B.M., and P.C.C. All authors contributed to preparing the draft and gave final approval of the manuscript for publication. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by BASF AS.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki (2013). Ethical approval for the trial was obtained from the University of Northumbria, Department of Psychology Ethics Committee (code SUB023; approved 9 February 2017).

Informed Consent Statement: Informed consent was obtained from all participants involved in the study.

Data Availability Statement: Data outputs for this study are available by contacting the corresponding author.

Acknowledgments: The authors would like to thank Hannah Avery and Ellen Smith for their assistance in collecting the blood samples. We also thank Annette West and Chris Gelauf who carried out the fatty acid analysis, as well as Per-Olof Larsson for his support throughout the project.

Conflicts of Interest: C.H. and S.O.H. are employees of BASF AS. P.C.C. is an advisor to and has previously received funding from BASF AS.

References
1. Frank, S.; Gonzalez, K.; Lee-Ang, L.; Young, M.C.; Tamez, M.; Mattei, J. Diet and Sleep Physiology: Public Health and Clinical Implications. Front. Neurol. 2017, 8. [CrossRef] [PubMed]
2. St-Onge, M.P.; Mikic, A.; Pietrolungo, C.E. Effects of Diet on Sleep Quality. Adv. Nutr. 2016, 7, 938–949. [CrossRef] [PubMed]
3. Ji, X.; Grandner, M.A.; Liu, J. The relationship between micronutrient status and sleep patterns: A systematic review. Public Health Nutr. 2017, 20, 687–701. [CrossRef] [PubMed]
4. Pusceddu, M.M.; Kelly, P.; Stanton, C.; Cryan, J.F.; Dinan, T.G. N-3 Polyunsaturated Fatty Acids through the Lifespan: Implication for Psychopathology. Int. J. Neuropsychopharmacol. 2016, 19, pyw078. [CrossRef]
5. Da Silva, A.X.; Lavialle, F.; Gentrot, G.; Guesnet, P.; Alessandri, J.M.; Lavialle, M. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J. Neurochem. 2002, 81, 1328–1337. [CrossRef]
6. Lavialle, M.; Champeil-Potokar, G.; Alessandri, J.M.; Balasse, L.; Guesnet, P.; Papillon, C.; Pévet, P.; Vancassel, S.; Vivien-Roels, B.; Denis, I. An (n-3) polyunsaturated fatty acid-deficient diet disturbs daily locomotor activity, melatonin rhythm, and striatal dopamine in syrian hamsters. J. Nutr. 2008, 138, 1719–1724. [CrossRef]
36. Günther, J.; Schulte, K.; Wenzel, D.; Malinowska, B.; Schlicker, E. Prostaglandins of the E series inhibit monoamine release via EP 3 receptors: Proof with the competitive EP 3 receptor antagonist L-826,266. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 2010, 381, 21. [CrossRef]
37. Monti, J.M. Serotonin control of sleep-wake behavior. *Sleep Med. Rev.* 2011, 15, 269–281. [CrossRef]
38. Murphy, R.; Gu, Q.; Marklund, M.; Riserus, U.; Virtanen, J.; Tintle, N.; Wood, A.; Gudnason, V.; Carnethon, M.; Harris, W.; et al. Omega-3 Fatty Acid Biomarkers and Sleep: Pooled Analysis of Prospective Studies in the Fatty Acids and Outcome Research Consortium (FORCE). *Curr. Dev. Nutr.* 2020, 4, 1460. [CrossRef]
39. Murphy, R.; Carnethon, M.; Harris, W.; Mello, V.D.; Uusitupa, M.; Tuomilehto, J.; Tuomilehto, H.; Lindberg, E.; Mozaffarian, D.; Gu, Q. Omega-3 and omega-6 Fatty Acid Biomarkers and Sleep Duration: Pooled Analysis from Five Prospective Studies in the Fatty Acids and Outcome Research Consortium (FORCE) (P08-116-19). *Curr. Dev. Nutr.* 2019, 3. [CrossRef]
40. Price, A.M.; Wake, M.; Ukoumunne, O.C.; Hiscock, H. Five-year follow-up of harms and benefits of behavioral infant sleep intervention: Randomized trial. *Pediatrics* 2012, 130, 643–651. [CrossRef]
41. Ellulu, M.S.; Khaza'ai, H.; Rahmat, A.; Patimah, I.; Abed, Y. Obesity can predict and promote systemic inflammation in healthy adults. *Int. J. Cardiol.* 2016, 215, 318–324. [CrossRef] [PubMed]
42. Ferrante, A., Jr. Obesity-induced inflammation: A metabolic dialogue in the language of inflammation. *J. Intern. Med.* 2007, 262, 408–414. [CrossRef] [PubMed]
43. Hargens, T.A.; Kaleth, A.S.; Edwards, E.S.; Butner, K.L. Association between sleep disorders, obesity, and exercise: A review. *Nat. Sci. Sleep* 2013, 5, 27. [CrossRef] [PubMed]